CL2022002368A1 - Hidrato cristalino de un compuesto inhibidor de jak - Google Patents
Hidrato cristalino de un compuesto inhibidor de jakInfo
- Publication number
- CL2022002368A1 CL2022002368A1 CL2022002368A CL2022002368A CL2022002368A1 CL 2022002368 A1 CL2022002368 A1 CL 2022002368A1 CL 2022002368 A CL2022002368 A CL 2022002368A CL 2022002368 A CL2022002368 A CL 2022002368A CL 2022002368 A1 CL2022002368 A1 CL 2022002368A1
- Authority
- CL
- Chile
- Prior art keywords
- crystalline hydrate
- inhibitor compound
- jak inhibitor
- hydrate
- crystalline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En el presente documento se proporciona un hidrato cristalino del compuesto de fórmula 1: También se proporcionan en este documento composiciones farmacéuticas que comprenden dicho hidrato cristalino, métodos para usar dicho hidrato cristalino para tratar enfermedades respiratorias y procesos útiles para preparar dicho hidrato cristalino.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062983931P | 2020-03-02 | 2020-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022002368A1 true CL2022002368A1 (es) | 2023-04-21 |
Family
ID=75143791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022002368A CL2022002368A1 (es) | 2020-03-02 | 2022-08-31 | Hidrato cristalino de un compuesto inhibidor de jak |
Country Status (16)
Country | Link |
---|---|
US (2) | US11702415B2 (es) |
EP (1) | EP4114836A1 (es) |
JP (1) | JP2023516640A (es) |
KR (1) | KR20220149585A (es) |
CN (1) | CN115190878A (es) |
AR (1) | AR121483A1 (es) |
AU (1) | AU2021232100A1 (es) |
BR (1) | BR112022017398A2 (es) |
CA (1) | CA3172338A1 (es) |
CL (1) | CL2022002368A1 (es) |
CO (1) | CO2022012476A2 (es) |
IL (1) | IL295613A (es) |
MX (1) | MX2022010795A (es) |
TW (1) | TW202144343A (es) |
WO (1) | WO2021178991A1 (es) |
ZA (1) | ZA202209617B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210056381A (ko) * | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 디메틸 아미노 아제티딘 아마이드 |
TW202144343A (zh) * | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
WO2023230236A1 (en) | 2022-05-26 | 2023-11-30 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ttk阻害作用を有するインダゾール誘導体 |
EP2414340A1 (en) | 2009-04-03 | 2012-02-08 | Dainippon Sumitomo Pharma Co., Ltd. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
PL3001903T3 (pl) | 2009-12-21 | 2018-03-30 | Samumed, Llc | 1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne |
US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
EP3318565B1 (en) | 2013-12-05 | 2021-04-14 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
TN2016000503A1 (en) | 2014-05-14 | 2018-04-04 | Pfizer | Pyrazolopyridines and pyrazolopyrimidines |
WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
CA3037243A1 (en) | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1 h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
KR20180073687A (ko) | 2015-11-03 | 2018-07-02 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물 |
WO2017077288A1 (en) * | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
US20180258546A1 (en) | 2017-03-09 | 2018-09-13 | Lam Research Corporation | Electroplating apparatus and methods utilizing independent control of impinging electrolyte |
EA037748B1 (ru) | 2017-03-09 | 2021-05-18 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Конденсированные имидазо-пиперидиновые ингибиторы jak |
EP3619208B1 (en) | 2017-05-01 | 2023-06-07 | Theravance Biopharma R&D IP, LLC | Crystalline forms of a jak inhibitor compound |
AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
CA3059785A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
SG11202101751XA (en) | 2018-09-04 | 2021-03-30 | Theravance Biopharma R&D Ip Llc | 5 to 7 membered heterocyclic amides as jak inhibitors |
KR20210056381A (ko) | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 디메틸 아미노 아제티딘 아마이드 |
TWI808250B (zh) | 2018-09-04 | 2023-07-11 | 美商施萬生物製藥研發 Ip有限責任公司 | 用於製備jak抑制劑之方法及其中間體 |
JP2022506111A (ja) | 2018-10-29 | 2022-01-17 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Jak阻害剤としての2-アザビシクロヘキサン化合物 |
PE20212069A1 (es) | 2019-02-25 | 2021-10-26 | Henan Medinno Pharmaceutical Tech Co Ltd | Compuesto inhibidor de jak y uso del mismo |
US11406640B2 (en) | 2019-03-05 | 2022-08-09 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
CN112279848A (zh) | 2019-07-25 | 2021-01-29 | 四川海思科制药有限公司 | 一种泛JAKs抑制剂及其用途 |
TW202144343A (zh) * | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
-
2021
- 2021-02-26 TW TW110106884A patent/TW202144343A/zh unknown
- 2021-03-01 AR ARP210100530A patent/AR121483A1/es unknown
- 2021-03-01 JP JP2022552324A patent/JP2023516640A/ja active Pending
- 2021-03-01 MX MX2022010795A patent/MX2022010795A/es unknown
- 2021-03-01 AU AU2021232100A patent/AU2021232100A1/en active Pending
- 2021-03-01 BR BR112022017398A patent/BR112022017398A2/pt unknown
- 2021-03-01 EP EP21713868.4A patent/EP4114836A1/en active Pending
- 2021-03-01 CN CN202180017759.9A patent/CN115190878A/zh active Pending
- 2021-03-01 KR KR1020227034088A patent/KR20220149585A/ko unknown
- 2021-03-01 US US17/249,375 patent/US11702415B2/en active Active
- 2021-03-01 WO PCT/US2021/070207 patent/WO2021178991A1/en active Application Filing
- 2021-03-01 IL IL295613A patent/IL295613A/en unknown
- 2021-03-01 CA CA3172338A patent/CA3172338A1/en active Pending
-
2022
- 2022-08-29 ZA ZA2022/09617A patent/ZA202209617B/en unknown
- 2022-08-31 CO CONC2022/0012476A patent/CO2022012476A2/es unknown
- 2022-08-31 CL CL2022002368A patent/CL2022002368A1/es unknown
-
2023
- 2023-05-31 US US18/326,732 patent/US20240025897A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2022012476A2 (es) | 2022-09-20 |
JP2023516640A (ja) | 2023-04-20 |
CA3172338A1 (en) | 2021-09-10 |
AU2021232100A1 (en) | 2022-10-20 |
US20240025897A1 (en) | 2024-01-25 |
WO2021178991A1 (en) | 2021-09-10 |
US11702415B2 (en) | 2023-07-18 |
US20210269437A1 (en) | 2021-09-02 |
IL295613A (en) | 2022-10-01 |
KR20220149585A (ko) | 2022-11-08 |
ZA202209617B (en) | 2023-04-26 |
MX2022010795A (es) | 2022-11-30 |
EP4114836A1 (en) | 2023-01-11 |
AR121483A1 (es) | 2022-06-08 |
BR112022017398A2 (pt) | 2022-10-18 |
TW202144343A (zh) | 2021-12-01 |
CN115190878A (zh) | 2022-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022002368A1 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
AR111495A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
ECSP22077299A (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k | |
NI201800093A (es) | Inhibidores de mcl1 macrocíclicos para tratar el cáncer | |
AR116115A1 (es) | Dimetil amino azetidina amidas como inhibidores de jak | |
ECSP20044709A (es) | Inhibidores de sarcómero cardíaco | |
CO2022002804A2 (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos | |
PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
ECSP20035222A (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa | |
CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
ECSP13012494A (es) | Inhibidores de oxadiazol de la producción de leucotrieno. | |
AR066972A1 (es) | Derivados azapeptidicos | |
CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
UY38665A (es) | Agentes antiproliferativos para el tratamiento de pah | |
ZA202109193B (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
CL2020001244A1 (es) | Inhibidores de inmunoproteasoma. | |
CO6710902A2 (es) | Inhibidores de oxadiazol de la producción de leucotrienos | |
AR123285A1 (es) | Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9 | |
BR112023003744A2 (pt) | Composto, e, composição farmacêutica para o tratamento de doenças associadas a diacilglicerol aciltransferase 2 | |
CL2023000648A1 (es) | Métodos para tratar enfermedades o afecciones mediadas por pde iv | |
AR107164A1 (es) | INHIBIDORES DE QUINASA p38 |